Invivyd, Inc. (NASDAQ:IVVD) Stock Has Consensus Target Price of $10.00 According to Brokerages

Invivyd, Inc. (NASDAQ:IVVD) has earned a consensus recommendation of “Hold” from the six analysts that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $10.00.

IVVD has been the topic of a number of recent research reports. HC Wainwright reissued a “buy” rating on shares of Invivyd in a research report on Tuesday, September 29th. BTIG Research reiterated a “buy” rating on shares of Invivyd in a research note on Monday, September 14th. Weiss Ratings raised Invivyd from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, September 8th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Invivyd in a research report on Thursday, August 27th.

Insider Transactions at Invivyd

In other Invivyd news, insider Jill Andersen sold 37,256 shares of Invivyd stock in a transaction on Monday, August 17th. The shares were sold at an average price of $0.72, for a total value of $26,824.32. Following the completion of the transaction, the insider owned 314,480 shares of the company’s stock, valued at $226,425.60. The trade was a 10.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 228,024 shares of company stock worth $176,540 in the last quarter. Company insiders own 12.25% of the company’s stock.

Hedge Funds Weigh In On Invivyd

Institutional investors have recently made changes to their positions in the stock. United Capital Financial Advisors LLC bought a new stake in shares of Invivyd in the 2nd quarter worth approximately $84,000. Bank of America Corp DE bought a new stake in Invivyd in the second quarter valued at $311,000. Jupiter Topco LLC bought a new stake in Invivyd in the second quarter valued at $30,048,000. ADAR1 Capital Management LLC acquired a new position in shares of Invivyd during the second quarter valued at $3,322,000. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of Invivyd during the second quarter valued at approximately $52,000. 70.36% of the stock is owned by institutional investors.

Invivyd Trading Up 0.5%

Shares of Invivyd stock opened at $0.61 on Friday. Invivyd has a twelve month low of $0.53 and a twelve month high of $3.07. The business’s fifty day moving average price is $0.81 and its 200 day moving average price is $0.97.

Invivyd (NASDAQ:IVVD) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.03). The firm had revenue of $14.29 million for the quarter, compared to analyst estimates of $14.40 million. Invivyd had a negative return on equity of 59.73% and a negative net margin of 183.90%. On average, research analysts predict that Invivyd will post -0.51 earnings per share for the current fiscal year.

About Invivyd

Invivyd, Inc is a biotechnology company focused on developing antibody-based medicines designed to prevent and treat infectious diseases. The company uses its antibody discovery and engineering technologies to create broadly neutralizing antibodies intended to remain effective as viruses evolve.

Invivyd’s lead product is pemivibart, marketed in the United States as PEMGARDA. The U.S. Food and Drug Administration granted pemivibart an Emergency Use Authorization in 2024 for pre-exposure prophylaxis against COVID-19 in certain individuals who are moderately or severely immunocompromised and unlikely to mount an adequate immune response to vaccination.